ProFactor Pharma closed its Series A round of financing in August 2013. The funding was provided principally by members of the Business Angel Syndicate Kelvin Capital, Glasgow, and the Scottish Investment Bank Co-investment Fund. Some of the existing shareholders, including the major shareholder Ingenza Biologics Ltd, also participated in the round.

See the Young Company finance article YCF Article